Simoctocog alfa for haemophilia A: No suitable data

No added benefit can be derived from the dossier after the study of the use of Simoctocog alfa for haemophilia A. The duration of the direct comparative studies was too short and the study pool on one-arm studies with the comparator therapy was incomplete, experts say.



from News -- ScienceDaily http://ift.tt/1vPrfed via Karis World